Stock Events

Stock Events

StemRIM 

$2.08
5
+$0+0% Tuesday 12:05

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
129.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17JunExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.06
-0.05
-0.05
-0.04
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-26.84MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SRIMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company Limited is a major competitor in the biotechnology and pharmaceutical sectors, directly competing with StemRIM in the development of regenerative medicine and therapies.
Astellas Pharma
4503.TSE
Mkt Cap3.68T
Astellas Pharma Inc. competes in the pharmaceutical and biotechnology industries, focusing on innovative therapies that may overlap with StemRIM's regenerative medicine projects.
Shionogi &.
4507.TSE
Mkt Cap2.12T
Shionogi & Co., Ltd. is involved in the research and development of pharmaceutical products, including regenerative medicine, making it a direct competitor to StemRIM.
Chugai Pharmaceutical
4519.TSE
Mkt Cap6.03T
Chugai Pharmaceutical Co., Ltd. specializes in biopharmaceuticals, competing with StemRIM in the field of regenerative medicine and biotechnological research.
Daiichi Sankyo.
4568.TSE
Mkt Cap8.21T
Daiichi Sankyo Company, Limited operates in the pharmaceutical sector, focusing on innovative drugs that could compete with StemRIM's regenerative medicine solutions.
OtsukaLtd.
4578.TSE
Mkt Cap2.43T
Otsuka Holdings Co., Ltd. offers a diverse portfolio of pharmaceutical products, including those in the realm of regenerative medicine, positioning it as a competitor to StemRIM.
Eisai
4523.TSE
Mkt Cap1.69T
Eisai Co., Ltd. is known for its research and development in the pharmaceutical field, including areas that overlap with StemRIM's focus on regenerative medicine.
Kyowa Kirin.
4151.TSE
Mkt Cap1.75T
Kyowa Kirin Co., Ltd. focuses on pharmaceuticals and biotechnologies, including regenerative medicine, making it a competitor in the same niche as StemRIM.
Takeda Pharmaceutical
4502.TSE
Mkt Cap6.05T
Tsumura & Co. is involved in the healthcare and pharmaceutical industry, with a focus on traditional and innovative medicines that could compete with StemRIM's offerings.
Sumitomo Pharma.
4506.TSE
Mkt Cap419.94B
Sumitomo Pharma Co., Ltd. operates in the pharmaceutical sector, developing products that could rival StemRIM's regenerative medicine and biotechnology solutions.

About

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Show more...
CEO
ISIN
JP3399690001

Listings

OTC Link
US
SRIMF
TSE
JP
4599.TSE

0 Comments

Share your thoughts

FAQ

What is StemRIM stock price today?▼
The current price of SRIMF is $2.08 USD — it has increased by +0% in the past 24 hours. Watch StemRIM stock price performance more closely on the chart.
What is StemRIM stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange StemRIM stocks are traded under the ticker SRIMF.
What is StemRIM market cap?▼
Today StemRIM has the market capitalization of 129.24M
When is the next StemRIM earnings date?▼
StemRIM is going to release the next earnings report on June 17, 2026.
What were StemRIM earnings last quarter?▼
SRIMF earnings for the last quarter are -0.04 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is StemRIM revenue for the last year?▼
StemRIM revenue for the last year amounts to 0 USD.
What is StemRIM net income for the last year?▼
SRIMF net income for the last year is -26.84M USD.
When did StemRIM complete a stock split?▼
StemRIM has not had any recent stock splits.